Vesugen (KED, T-38) Research: Evidence Map and Verifiable PubMed Sources#

This page maps the verifiable research base for Vesugen (KED, Lys-Glu-Asp, designated T-38) against standard evidence-quality criteria. The headline is that one strong PubMed-indexed study -- Khavinson et al. 2021 (PMID 34071923; DOI 10.3390/ph14060515)¹ -- co-tests KED with EDR (Pinealon) in a 5xFAD Alzheimer's mouse model. Most additional reports, particularly the SIRT1/Ki-67 vascular-endothelial claims, sit in Russian-language Khavinson-program literature and have not been independently replicated.

The Canonical PubMed Citation#

Khavinson 2021 — 5xFAD Alzheimer's Mouse Model (PMID 34071923)#

The strongest single Vesugen citation is Khavinson V, Ilina A, Kraskovskaya N, et al., Pharmaceuticals 2021 (PMID 34071923; DOI 10.3390/ph14060515)¹.

Design and findings:

• Model: 5xFAD transgenic mouse model of Alzheimer's disease
• Intervention: EDR (Pinealon) and KED (Vesugen) tripeptides, 400 mcg/kg/day intraperitoneal injection from 2 to 4 months of age
• Primary readout: dendritic spine density in cortical and hippocampal neurons
• Result: EDR and KED prevented age- and pathology-associated dendritic spine loss
• Mechanistic data: in-silico molecular docking predicted EDR and KED binding to promoter regions of CASP3, NES, GAP43, APOE, SOD2, PPARA, and PPARG -- all genes implicated in AD pathology
• Authors' interpretation: epigenetic / gene-regulatory mechanism for the neuroprotective effect

What the Study Does Not Show#

The 2021 paper is the best Vesugen evidence available but has important boundaries:

• Not a vascular study. The model is neural, not vascular endothelium -- the SIRT1/Ki-67 vascular claims rest elsewhere.
• Co-administration with EDR. For most endpoints, KED was tested alongside EDR rather than alone, complicating attribution.
• In-silico docking is not direct binding evidence. The promoter-binding claims rely on computational prediction; direct biophysical confirmation is absent.
• Mouse model. Translation to human vascular or neurological outcomes has not been performed.
• Khavinson-program authorship. As with other short-peptide bioregulator literature, the study comes from the original research program; independent replication is what remains needed.

Russian-Language and Non-PubMed Sources#

Additional Vesugen-related reports describe:

• SIRT1 and Ki-67 expression changes in cultured endothelial cells and aged-rat vascular tissue
• Endothelial function readouts (e.g., vasodilator response) in aged-rat models
• Small-cohort clinical observations from Russian bioregulation clinics

These reports are not PubMed-indexed to the standard required for direct citation here. We do not pin specific numbers to them because we cannot verify them against the original sources to PubMed/DOI standards.

What's Missing From the Evidence Base#

A complete evidence package for Vesugen as a vascular intervention would require at minimum:

1. Independent replication of the SIRT1/Ki-67 vascular effects by labs outside the Khavinson program
2. Direct biophysical evidence of KED-DNA binding (NMR, surface plasmon resonance, isothermal titration calorimetry) to confirm the proposed mechanism
3. Pharmacokinetic data: oral and parenteral absorption, plasma half-life, tissue distribution, clearance
4. At least one randomised controlled trial for a clinically meaningful vascular endpoint (endothelial function via flow-mediated dilation, arterial stiffness, blood pressure, or hard cardiovascular outcomes)
5. Studies separating KED-specific effects from EDR effects when the two are co-administered
6. Long-term safety and carcinogenicity data, given the gene-expression-modulating mechanism

None of these is currently available in PubMed-indexed form as of June 2026.

Comparison to Better-Studied Khavinson Peptides#

Vesugen's evidence base is slightly stronger than Prostamax's (it has a 5xFAD model citation rather than just an in-vitro lymphocyte study) but is still well below the threshold for any clinical claim.

Bottom Line#

Vesugen (KED) has one solid PubMed-indexed citation -- a 5xFAD mouse study reporting dendritic spine preservation when co-administered with EDR (PMID 34071923) -- and a body of Russian-language vascular and SIRT1/Ki-67 reports that have not been independently replicated. As of June 2026, Vesugen cannot be supported as a clinical vascular intervention; it should be treated as an early-stage research compound.

References#

Footnotes#

1. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides -- Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021. PMID: 34071923. DOI: 10.3390/ph14060515. ↩ ↩²